Cross Herb
SEC-identified person · CIK 1230721 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Jasper Therapeutics, Inc. JSPR | Chief Financial Officer | filed 2023–2026 |
| Brookline Capital Acquisition Corp. BCACU | Director | filed 2022–2023 |
| Atreca, Inc. BCEL | Chief Financial Officer | filed 2019–2023 |
| Armo Biosciences, Inc. ARMO | Chief Financial Officer | filed 2018–2018 |
| Kalobios Pharmaceuticals INC KBIOQ | Chief Financial Officer | filed 2013–2015 |
| Affymax INC AFFY | VP, Fin. & Chief Acct. Officer | filed 2010–2013 |
| Facet Biotech Corp FACT | VP of Finance/Prin Acctg Off | filed 2008–2010 |
| Protein Design Labs INC/DE pdli | Corp Controller/Prin Actg Ofcr | filed 2007–2008 |
| Neoforma INC NEOF | VP of Finance | filed 2006–2006 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.